The company trades steel products, chemicals, and other industrial goods, while also managing a portfolio of investments in shares and securities.
The company lacks a competitive moat as evidenced by an average ROCE of just 1.3%, which is significantly below the cost of capital. There is no evidence of brand power or cost advantages, and the business relies on low-margin trading in highly fragmented markets.
Management has prioritized interest-free loans to related parties and capital-raising through rights issues over generating organic returns. The conversion of loans into equity and high related-party transaction limits suggest capital is used to support a network of affiliated companies rather than independent growth.
The investment collapsed as the company's role as a de facto financing vehicle for related parties finally hollowed out the remaining equity. While the business nominally operated in services, the persistent diversion of capital through interest-free loans to affiliates meant that no productive reinvestment occurred. As the core trading margins remained pinned below the cost of capital, the eventual exhaustion of non-operational assets like land sales left the company unable to cover its overhead, leading to a slow-motion liquidation where minority shareholders were the last to be served.
RichFakir rates Lesha Industries Ltd's business quality as poor — 17/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Lesha Industries Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Lesha Industries Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Lesha Industries Ltd's fair value is about ₹0 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →